Pancreatic Cancer News
Scientists have shown it is possible to reverse a key process that allows pancreatic cancer cells to grow and spread around the body.
Researchers at the Herbert Irving Comprehensive Cancer Center (HICCC) at NewYork-Presbyterian/Columbia University Irving Medical Center have discovered a protein whose level of expression functions as a molecular switch between primary cancer growth and metastatic dissemination in PDA cells.
HonorHealth researchers developed a novel drug combination therapy for pancreatic cancer patients that has become part of the new National Comprehensive Cancer Network guidelines for the disease, the system shared with Becker’s.
Between 1995 and 2018, non-Hispanic White and Hispanic women in the United States experienced the greatest increases in early-onset pancreatic cancer (EOPC) incidence, according to study results published in Gastroenterology.
The FDA granted an orphan drug designation to QXL138AM, a first in class masked Immunocytokine (MIC), for the treatment of patients with pancreatic cancers, according to Nammi Therapeutics, Inc.
In this video, Robert Vonderheide, MD, DPhil, discussed the results of the phase 2 randomized study of chemoimmunotherapy for patients with metastatic pancreatic cancer.
Novel Natrunix Treatment Shows Promise in Combination Chemotherapy for Treatment of Pancreatic Cancer
Perhaps the best known of all the cancer predisposition genes are inherited mutations in the genes BRCA1 and BRCA2. They were originally associated with an increased risk of breast and ovarian cancers. Later studies revealed they also raised the risk of prostate and pancreatic cancers, and in some cases, melanoma.